Prenatal and Reproductive Genetic Testing Market Size & Share 2026-2035

Prenatal and Reproductive Genetic Testing Market Size

The global prenatal and reproductive genetic testing market was valued at USD 7.8 billion in 2025. The market is expected to reach from USD 8.6 billion in 2026 to USD 22.4 billion in 2035, growing at a CAGR of 11.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is witnessing robust growth, driven by the increasing demand for early genetic risk assessment, rising maternal age, growing prevalence of inherited genetic disorders, and expanding adoption of assisted reproductive technologies (ART). Increasing awareness of reproductive health, advancements in molecular diagnostics, and wider availability of genetic screening services are further accelerating the adoption of prenatal and reproductive genetic testing.

According to the World Health Organization (WHO), approximately 240,000 newborns die within the first 28 days of life each year due to congenital disorders, while hundreds of thousands more are affected by genetic and chromosomal abnormalities that contribute to lifelong disabilities. These trends are increasing the demand for comprehensive genetic testing solutions, including non-invasive prenatal testing (NIPT), carrier screening, preimplantation genetic testing (PGT), prenatal diagnostic testing, and other reproductive genomics services.

The prenatal & reproductive genetic testing market comprises a broad range of genetic screening and diagnostic tests used before conception, during fertility treatment, and throughout pregnancy to identify inherited genetic conditions, chromosomal abnormalities, and fetal genetic disorders. The market includes carrier screening, preimplantation genetic testing (PGT-A, PGT-M, and PGT-SR), non-invasive prenatal testing (NIPT), maternal serum screening, nuchal translucency ultrasound, chorionic villus sampling (CVS), amniocentesis, and other prenatal diagnostic services. These technologies enable prospective parents and healthcare providers to assess genetic risks, support informed reproductive decisions, improve IVF outcomes, facilitate early diagnosis, and enable timely clinical intervention.

Major participants operating in the prenatal & reproductive genetic testing market include Natera, Illumina, F. Hoffmann-La Roche Ltd., Labcorp, Quest Diagnostics, Eurofins Scientific, Myriad Genetics, BGI Genomics, Thermo Fisher Scientific, and Revvity. These companies compete through comprehensive prenatal and reproductive testing portfolios, strategic collaborations with hospitals, fertility clinics, and diagnostic laboratories, continued investments in next-generation sequencing and molecular diagnostics, and expansion of reproductive genomics capabilities to improve testing accuracy, accessibility, and clinical utility.

The prenatal & reproductive genetic testing market expanded from USD 5.7 billion in 2022 to USD 7 billion in 2024, reflecting strong historical growth driven by increasing utilization of prenatal screening programs, growing adoption of IVF and other assisted reproductive technologies, rising awareness of inherited genetic disorders, and continuous advancements in sequencing and molecular diagnostic technologies. The widespread adoption of non-invasive prenatal testing (NIPT) as a first-line prenatal screening method and the increasing integration of preimplantation genetic testing (PGT) into IVF treatment protocols have further strengthened market growth during the historical period.

The market is expected to maintain strong momentum throughout the forecast period, supported by the growing number of pregnancies among women of advanced maternal age, increasing global demand for fertility treatments, and expanding adoption of personalized reproductive healthcare. Rising awareness of genetic disease prevention, greater acceptance of preconception carrier screening, increasing utilization of embryo genetic testing during IVF procedures, and favorable technological advancements in reproductive genomics are expected to continue driving demand for prenatal and reproductive genetic testing services worldwide.

Prenatal and Reproductive Genetic Testing Market Trends

• The prenatal & reproductive genetic testing market is expected to witness substantial growth, driven by the increasing prevalence of genetic and chromosomal disorders, rising maternal age, growing utilization of assisted reproductive technologies (ART), particularly in vitro fertilization (IVF), and expanding awareness of early genetic risk assessment and disease prevention. Furthermore, the increasing adoption of non-invasive prenatal testing (NIPT), carrier screening, and preimplantation genetic testing (PGT) is accelerating market expansion worldwide.
• As reproductive healthcare gains greater importance globally, the demand for comprehensive prenatal and reproductive genetic testing services continues to rise. This has resulted in the expansion of fertility clinics, maternal-fetal medicine centers, genetic testing laboratories, and reproductive health facilities across both developed and emerging economies.
• The growing number of specialized reproductive healthcare facilities is driving demand for advanced molecular diagnostics, next-generation sequencing (NGS), chromosomal analysis technologies, and genetic counseling services capable of delivering accurate, reliable, and timely genetic risk assessments.
• The increasing number of IVF procedures performed worldwide, coupled with the trend toward delayed pregnancies and advanced maternal age, has significantly expanded the addressable patient population requiring carrier screening, embryo genetic testing, preimplantation genetic testing (PGT), and prenatal genetic screening. Additionally, growing awareness of inherited disorders, fetal health, and personalized reproductive planning continues to support the adoption of genetic testing services.
• Continuous technological advancements in cell-free DNA (cfDNA) analysis, next-generation sequencing (NGS), chromosomal microarray analysis (CMA), digital PCR, and AI-enabled genomic interpretation are enhancing test accuracy, improving detection rates, reducing turnaround times, and expanding the clinical utility of prenatal and reproductive genetic testing. Ongoing investments by market participants in these advanced technologies are expected to further strengthen market growth.
• The rising burden of inherited genetic disorders and chromosomal abnormalities, including Down syndrome, cystic fibrosis, spinal muscular atrophy (SMA), thalassemia, fragile X syndrome, and other monogenic diseases, continues to reinforce the importance of early genetic screening, reproductive planning, and preventive healthcare, thereby driving demand for prenatal and reproductive genetic testing solutions.
• Governments, healthcare organizations, and professional medical societies across several countries are increasingly supporting prenatal screening programs, carrier screening initiatives, genetic counseling services, and maternal-fetal health policies aimed at improving pregnancy outcomes and reducing the burden of genetic disorders. These initiatives are encouraging broader adoption of prenatal and reproductive genetic testing services and are expected to sustain long-term market growth

Prenatal and Reproductive Genetic Testing Market Analysis

Based on the products and services, the prenatal and reproductive genetic testing market is segmented into kits & reagents and software & services. The kits & reagents segment asserted its dominance in the market by securing a significant market share of 58.3% in 2025 owing to its indispensable role in genetic screening and diagnostic workflows, as well as its recurring consumption pattern, growing at a CAGR of 11% during the forecast period.

• Kits & reagents comprise a wide range of consumables, including NGS library preparation kits, PCR reagents, cell-free DNA (cfDNA) extraction kits, chromosomal microarray consumables, fluorescence in-situ hybridization (FISH) probes, and other molecular diagnostic reagents used in prenatal and reproductive genetic testing.
• These products are essential across virtually all testing workflows, including non-invasive prenatal testing (NIPT), carrier screening, chorionic villus sampling (CVS), amniocentesis-based genetic testing, and preimplantation genetic testing (PGT), resulting in consistent demand from diagnostic laboratories, hospitals, and fertility clinics.
• Increasing adoption of next-generation sequencing (NGS), rising prenatal screening volumes, and growing utilization of embryo genetic testing during IVF procedures continue to drive demand for kits and reagents. Moreover, the recurring consumption of laboratory consumables makes this segment the largest revenue contributor in the market.
• The software & services segment accounted for a significant share of the market in 2025 and is expected to grow at a CAGR of 11.4% during the forecast period. Growth is driven by increasing demand for genomic data analysis, bioinformatics platforms, laboratory workflow management solutions, genetic counseling services, and outsourced prenatal and reproductive genetic testing services.

Based on test type, the prenatal and reproductive genetic testing market is divided into prenatal tests and reproductive genetic tests. The prenatal tests segment dominated the market and is expected to reach USD 16.1 billion within the forecast period.

• Prenatal genetic testing has become an integral component of modern obstetric care by enabling the early detection of chromosomal abnormalities, fetal genetic disorders, and inherited conditions during pregnancy.
• The shift from invasive diagnostic procedures toward highly accurate, blood-based screening methods such as non-invasive prenatal testing (NIPT) has significantly accelerated testing adoption among expectant parents, particularly in developed healthcare markets.
• Expanding reimbursement coverage, increasing pregnancy monitoring rates, and growing awareness of preventive maternal-fetal healthcare continue to strengthen the commercial adoption of prenatal genetic testing worldwide.
• The reproductive genetic tests segment accounted for a significant share of the market in 2025 and is anticipated to grow at a CAGR of 11.3%, driven by the rapid expansion of fertility treatment services and increasing integration of genetic testing into assisted reproductive technology (ART) and IVF workflows.

Based on technology, the prenatal and reproductive genetic testing market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), chromosomal microarray analysis (CMA), fluorescence in-situ hybridization (FISH) and other technologies. The next-generation sequencing (NGS) segment dominated the market in 2025 with a market share of 48.1%.

• NGS enables high-throughput genomic analysis with superior sensitivity and accuracy, making it the preferred technology for detecting a broad spectrum of genetic variants in prenatal and reproductive genetic testing.
• Growing demand for comprehensive genetic screening panels, declining sequencing costs, and continuous improvements in sequencing throughput and accuracy have accelerated global adoption of NGS-based testing platforms.
• The increasing focus on precision medicine and personalized reproductive healthcare is further encouraging healthcare providers, fertility specialists, and diagnostic laboratories to incorporate NGS into routine clinical practice.
• The polymerase chain reaction (PCR) segment accounted for a significant share of the market in 2025 and is expected to grow at a CAGR of 11.6%, driven by its established clinical utility, rapid turnaround time, cost-effectiveness, and widespread use in carrier screening and targeted prenatal genetic testing.
• The chromosomal microarray analysis (CMA) segment is projected to expand at a CAGR of 11.1%, supported by increasing utilization for detecting submicroscopic chromosomal abnormalities and copy number variations (CNVs) that may not be identified using conventional cytogenetic techniques.

Based on the application, the prenatal and reproductive genetic testing market is segmented into chromosomal abnormalities, single gene / monogenic disorders, carrier status assessment, embryo screening & selection and other applications. The chromosomal abnormalities segment dominated in 2025 and is anticipated to grow at a CAGR of 10.9% during the forecast period.

• Prenatal screening programs primarily focus on detecting chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), and sex chromosome aneuploidies, making this the largest application segment.
• Increasing maternal age, which is associated with a higher risk of fetal chromosomal abnormalities, continues to drive testing volumes globally.
• Expanding implementation of routine prenatal screening guidelines, improved access to advanced genomic technologies, and increasing awareness of early fetal genetic assessment continue to reinforce the segment's leading market position.
• The single gene/monogenic disorders segment accounted for a significant share of the market in 2025 and is projected to grow at a CAGR of 11.4%, driven by increasing awareness and screening for inherited disorders such as cystic fibrosis, spinal muscular atrophy (SMA), fragile X syndrome, and thalassemia.
• The carrier status assessment segment is expected to register a CAGR of 11.1% during the forecast period, supported by growing adoption of preconception genetic screening, increasing availability of expanded carrier screening panels, and rising emphasis on reproductive planning among prospective parents.

Based on the end use, the prenatal and reproductive genetic testing market is categorized into hospitals, diagnostic laboratories, fertility clinics / IVF centers, maternity & specialty clinics and other end users. The diagnostic laboratories segment dominated the market in 2025 with a market share of 35.9%.

• Increasing complexity of prenatal and reproductive genetic testing has strengthened the role of specialized diagnostic laboratories equipped with advanced molecular diagnostic technologies such as NGS, CMA, PCR, and other genomic testing platforms.
• Hospitals, obstetricians, and fertility specialists increasingly rely on centralized laboratories for highly accurate genetic analysis, comprehensive result interpretation, quality assurance, and faster turnaround times.
• The presence of major commercial genetic testing providers, including Natera, Labcorp, Quest Diagnostics, Eurofins Scientific, and other specialized genomics laboratories, continues to reinforce the leadership of this segment.
• The hospitals segment accounted for a significant share of the market in 2025 and is expected to grow at a CAGR of 10.9%, driven by increasing integration of prenatal genetic screening into routine obstetric care, expanding maternal-fetal medicine services, and greater availability of in-house genetic testing capabilities.
• The fertility clinics/IVF centers segment is projected to register a CAGR of 11.6% during the forecast period, supported by the growing utilization of assisted reproductive technologies (ART), rising demand for embryo selection, and expanding adoption of preimplantation genetic testing (PGT-A, PGT-M, and PGT-SR) to improve IVF success rates and reduce the risk of inherited genetic disorders.

North America Prenatal and Reproductive Genetic Testing Market

The North America market dominated the global market with the highest market share of 41.2% in 2025.

• The U.S. prenatal & reproductive genetic testing market was valued at USD 5.2 billion in 2022 and USD 5.8 billion in 2023. The market grew from USD 6.4 billion in 2024 to USD 7.1 billion in 2025.
• The U.S. continues to be the largest contributor to regional growth, supported by the extensive use of assisted reproductive technologies. According to the CDC, 435,426 ART cycles were performed in the U.S. in 2022, resulting in 94,039 live-birth deliveries, driving strong demand for preimplantation genetic testing (PGT), carrier screening, and embryo genetic assessment.
• High awareness of chromosomal abnormalities, favorable reimbursement coverage for prenatal screening, and widespread adoption of non-invasive prenatal testing (NIPT) continue to strengthen market growth across the region.
• The presence of leading genetic testing companies, advanced sequencing laboratories, and specialized fertility centers further reinforces North America's leadership in the market.

Europe Prenatal and Reproductive Genetic Testing Market

Europe market accounted for USD 2 billion in 2025 and is anticipated to show considerable growth over the forecast period.

• Increasing maternal age across several European countries, coupled with growing acceptance of prenatal and reproductive genetic screening, continues to drive market expansion.
• Countries including Germany, France, the UK, Italy, and Spain have well-established fertility treatment networks and comprehensive prenatal screening programs, resulting in higher adoption of NIPT, carrier screening, and preimplantation genetic testing (PGT).
• Supportive healthcare systems, increasing awareness of inherited genetic disorders, and greater integration of genomic technologies into routine obstetric and fertility care are expected to further accelerate regional market growth.
• Continuous investments in molecular diagnostics and reproductive genomics by healthcare providers and diagnostic laboratories are strengthening Europe's position in the global market.

Asia Pacific America Prenatal and Reproductive Genetic Testing Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 11.5% during the analysis timeframe.

• The region offers significant growth opportunities due to its large reproductive-age population, increasing infertility rates, rising healthcare expenditure, and improving access to advanced genetic testing services.
• Countries such as China, Japan, South Korea, and Australia are witnessing increasing adoption of IVF procedures and prenatal genetic testing, driving demand for carrier screening, embryo genetic testing, preimplantation genetic testing (PGT), and NIPT.
• Expanding availability of molecular diagnostic technologies, increasing awareness of inherited diseases, and supportive government initiatives focused on maternal and child healthcare are further contributing to regional market expansion.
• Growing investments in fertility clinics, genomic medicine, and precision diagnostics are expected to position Asia Pacific as the fastest-growing regional market.

Latin America Prenatal and Reproductive Genetic Testing Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• Countries such as Brazil and Mexico are witnessing increasing demand for fertility treatment services due to rising infertility rates, delayed parenthood, and growing awareness of reproductive health.
• Expanding implementation of prenatal screening programs and increasing awareness of inherited genetic disorders are driving the adoption of NIPT, carrier screening, prenatal diagnostic testing, and reproductive genetic testing across the region.
• Improvements in private healthcare infrastructure, rising investments in reproductive medicine, and expanding access to advanced molecular diagnostic technologies are expected to support continued market growth.
• Increasing collaboration between fertility clinics and diagnostic laboratories is further improving access to comprehensive prenatal and reproductive genetic testing services.

Middle East and Africa Prenatal and Reproductive Genetic Testing Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Market growth is supported by increasing investments in maternal healthcare, fertility treatment infrastructure, prenatal screening programs, and genetic disease prevention initiatives across several countries.
• In the Middle East, relatively high rates of inherited genetic disorders associated with consanguineous marriages are increasing the demand for carrier screening, premarital genetic testing, and reproductive genetic testing to reduce the incidence of hereditary diseases.
• In Africa, improving healthcare accessibility, expanding diagnostic laboratory networks, and growing awareness of prenatal healthcare and genetic disease prevention are creating new opportunities for market participants.
• Government-led maternal and child health programs, together with increasing adoption of molecular diagnostic technologies, are expected to support the long-term growth of the market across the MEA region.

Prenatal and Reproductive Genetic Testing Market Share

The prenatal & reproductive genetic testing market is moderately consolidated, characterized by the presence of large multinational diagnostics and genomics companies alongside specialized prenatal and reproductive health testing providers. Companies compete based on technological innovation, breadth of genetic testing portfolios, clinical accuracy, laboratory network strength, turnaround time, and partnerships with hospitals, fertility clinics, and healthcare systems. Key players include Natera, Illumina, F. Hoffmann-La Roche Ltd., Labcorp, and Quest Diagnostics, collectively accounting for approximately 65% of the total market.

Market participants are increasingly focusing on expanding their prenatal and reproductive genomics offerings through advancements in next-generation sequencing (NGS), cell-free DNA (cfDNA) analysis, carrier screening, and preimplantation genetic testing (PGT). Strategic initiatives such as product launches, laboratory network expansion, collaborations with fertility clinics, and investments in artificial intelligence-enabled genomic interpretation are intensifying competition and strengthening market positioning. Additionally, the growing emphasis on integrated reproductive healthcare solutions combining genetic testing, genetic counseling, and fertility services is further driving competitive differentiation across the industry.

Prenatal and Reproductive Genetic Testing Market Companies

Few of the prominent players operating in the prenatal and reproductive genetic testing industry include:

• BGI Genomics
• CooperSurgical
• Eurofins Scientific
• F. Hoffmann-La Roche
• Fulgent Genetics
• Genea Biomedx
• Igenomix
• Illumina
• Labcorp
• Myriad Genetics
• Natera
• Quest Diagnostics
• Revvity
• Sema4
• Thermo Fisher Scientific

• Natera

Natera is one of the leading players in the market, commanding a significant share of the global market through its comprehensive portfolio of prenatal and reproductive genetic testing solutions. The company continues to drive growth through flagship products such as Panorama NIPT, Horizon Carrier Screening, and Vistara single-gene NIPT, while strengthening its position through proprietary technology platforms, extensive physician adoption, and a strong focus on early genetic risk assessment and reproductive health services. The company also benefits from recurring testing revenues and continued expansion of its women's health testing portfolio.

• Illumina

Illumina is a prominent participant in the market, leveraging its leadership in next-generation sequencing (NGS) technologies that underpin a large proportion of global prenatal and reproductive genetic testing workflows. Through its sequencing platforms and reproductive genomics solutions, the company supports applications including NIPT, carrier screening, embryo genetic testing, and preimplantation genetic testing (PGT). Continuous investments in genomic innovation, workflow automation, and sequencing advancements enable Illumina to strengthen its market position and support the growing adoption of precision reproductive healthcare worldwide.

Prenatal and Reproductive Genetic Testing Industry News

• In May 2026, Natera announced a major enhancement to its Panorama Non-Invasive Prenatal Test (NIPT), powered by novel SNP-informed deep sequencing technology. The upgraded test reduced the no-call rate and improved performance in low fetal fraction pregnancies, strengthening Natera’s position in prenatal genetic screening.
• In April 2024, Revvity entered into a collaboration with RTI International’s Early Check program to provide genome sequencing services for newborn and genetic screening research. The partnership enables expanded screening for hundreds of childhood-onset genetic conditions and supports the integration of next-generation sequencing into population-scale screening programs.

The prenatal and reproductive genetic testing market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Products and Services

• Kits & Reagents
• Software & Services

Market, By Test Type       

• Prenatal tests         
  • Screening tests       
    • Non-invasive prenatal testing (NIPT)
    • Carrier screening
    • Serum screening
    • Nuchal translucency ultrasound
  • Diagnostic     
    • Chorionic villus sampling (CVS)
    • Amniocentesis
• Reproductive genetic tests           
  • Carrier screening     
  • Preimplantation genetic testing (PGT)      
    • PGT-A
    • PGT-M
    • PGT-SR
  • Embryo genetic testing       

Market, By Technology

• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR) 
• Chromosomal microarray analysis (CMA)
• Fluorescence in-situ hybridization (FISH) 
• Other technologies

Market, By Application

• Chromosomal abnormalities
• Single gene / monogenic disorders 
• Carrier status assessment
• Embryo screening & selection
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Fertility clinics / IVF centers
• Maternity & specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE